TY - JOUR
T1 - Plasma Fatty Acids in Chronic Kidney Disease
T2 - Nervonic Acid Predicts Mortality
AU - Shearer, Gregory C.
AU - Carrero, Juan J.
AU - Heimbürger, Olof
AU - Barany, Peter
AU - Stenvinkel, Peter
N1 - Funding Information:
Financial Disclosure: G.C.S. is supported by a grant from GlaxoSmithKline which studies the impact of n-3 FAs on lipid metabolism. G.C.S. additionally receives speakership honoraria from GlaxoSmithKline.
Funding Information:
The authors thank Brenda Collison-Schmidt for expert technical help and acknowledge the support from the Diabetes Theme Center at Karolinska Institutet and an unrestricted grant from Abbott laboratories, Nutritional Division .
PY - 2012/3
Y1 - 2012/3
N2 - Although the value of red blood cell fatty acids (FAs) in estimating risk for acute coronary syndrome in the general population is evident, the value of FAs in chronic kidney disease (CKD) is unknown. Here, we provide a pilot analysis in a spectrum of CKD patients. Plasma samples were obtained from 20 incident dialysis patients (CKD stage 5), matched with samples from 10 CKD stage 3-4 patients, and 10 control subjects. Whole plasma FAs were measured using gas chromatography. Whereas neither linoleic acid nor arachidonate acid were altered in CKD, metabolic intermediates of arachidonate synthesis (γ-linolenate and dihomo γ-linolenate) were reduced in CKD. Demming (orthogonal) correlation of FA abundance with estimated GFR identified several saturated and unsaturated FAs in addition to the intermediates; again, neither linoleate nor arachidonate were related. Follow-up data within the CKD stage 5 patients revealed that nervonic acid, a component of membrane sphingolipids and phosphatidylethanolamines, was a significant predictor of all-cause mortality; the age-adjusted relative risk for a 0.15% change is 2.1 (1.4, 3.7; 95% CI; P = .0008). These findings support the exploration of FAs in larger studies for validation of the role FAs in cardiovascular risk and mortality in CKD.
AB - Although the value of red blood cell fatty acids (FAs) in estimating risk for acute coronary syndrome in the general population is evident, the value of FAs in chronic kidney disease (CKD) is unknown. Here, we provide a pilot analysis in a spectrum of CKD patients. Plasma samples were obtained from 20 incident dialysis patients (CKD stage 5), matched with samples from 10 CKD stage 3-4 patients, and 10 control subjects. Whole plasma FAs were measured using gas chromatography. Whereas neither linoleic acid nor arachidonate acid were altered in CKD, metabolic intermediates of arachidonate synthesis (γ-linolenate and dihomo γ-linolenate) were reduced in CKD. Demming (orthogonal) correlation of FA abundance with estimated GFR identified several saturated and unsaturated FAs in addition to the intermediates; again, neither linoleate nor arachidonate were related. Follow-up data within the CKD stage 5 patients revealed that nervonic acid, a component of membrane sphingolipids and phosphatidylethanolamines, was a significant predictor of all-cause mortality; the age-adjusted relative risk for a 0.15% change is 2.1 (1.4, 3.7; 95% CI; P = .0008). These findings support the exploration of FAs in larger studies for validation of the role FAs in cardiovascular risk and mortality in CKD.
UR - http://www.scopus.com/inward/record.url?scp=84857362302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857362302&partnerID=8YFLogxK
U2 - 10.1053/j.jrn.2011.05.005
DO - 10.1053/j.jrn.2011.05.005
M3 - Article
C2 - 21775161
AN - SCOPUS:84857362302
SN - 1051-2276
VL - 22
SP - 277
EP - 283
JO - Journal of Renal Nutrition
JF - Journal of Renal Nutrition
IS - 2
ER -